BDX Stock Forecast & Price Target

Becton Dickinson reported strong financial performance in FQ3'25, with several segments achieving notable year-over-year sales growth, including a 5.3% increase in Medical Surgical Systems and a solid 4.8% growth in the MedTech business, contributing to an overall trend of consistent growth since the launch of BD 2025. The company's Life Sciences and Interventional segments also demonstrated resilience, with Peripheral Intervention sales rising 4.5% year-on-year, driven by advancements in Peripheral Vascular Disease treatments. Additionally, Becton Dickinson's international revenue, which constitutes 43% of total business, underpins a robust global market presence and enhances the company's positive outlook on future growth.

Becton Dickinson is experiencing a notable decline in sales growth, with the company recently lowering its organic revenue growth outlook for FY25 to 3.0-3.5% from an earlier projection of 4.0-4.5%. This reduction is attributed to headwinds such as decreased demand in the Biosciences sector due to government funding cuts and slower recovery in blood-culture testing, compounded by challenges in the Chinese market related to volume-based procurement. Furthermore, the company reported a 1.1% year-over-year decline in FQ3'25 sales, signaling ongoing difficulties across its various segments, particularly in Diagnostic Solutions and Biosciences, which negatively impacts its overall financial health.